Novan, which is planning to move its acne drug candidate into phase 3 trials next year, raised $50m in a Malin Corporation-backed round in March.

Catherex was spun out of Medigene, which held a 40% stake in the company, in 2010, and Amgen will pay $10.5m, with milestone payments to come.

Taiyu Capital, a corporate venturing unit of TigerMed, is among the investors in a round that increased the concussion response specialist's total funding to $13m.

The personalised medicine company has now raised $83m altogether from investors including Cincinnati Children's Hospital Medical Center and Mayo Clinic.

GlaxoSmithKline, Astellas, AbbVie and Novartis are among the investors in a $40m series B round for the cancer treatment developer.

Life sciences company Malin will invest up to $30m in the series A round closed by Poseida Therapeutics, which is working on liver disease and cancer treatments.

GlaxoSmithKline and Johnson & Johnson returned to join Sanofi in backing the biopharmaceutical company's series B round, bringing its total funding to more than $65m.

Zurich spinout Xeltis raises an additional $3.25m to continue development of its dissolvable implants.